Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
May 15th, 2021
7.7K views
This protocol describes the procedures to induce Acute Kidney Injury (AKI) in adult zebrafish using cisplatin as a nephrotoxic agent. We detailed the steps to evaluate the reproducibility of the technique and two techniques to analyze inflammation and cell death in the renal tissue, flow cytometry and TUNEL, respectively.
Overview
This protocol outlines the induction of Acute Kidney Injury (AKI) in adult zebrafish using cisplatin as a nephrotoxic agent. It details the evaluation of the technique's reproducibility and methods for analyzing inflammation and cell death in renal tissue.
Key Study Components
Area of Science
- Nephrology
- Neurobiology
- Zebrafish Models
Background
- Cisplatin is a chemotherapy agent that can induce nephrotoxicity.
- Understanding AKI mechanisms is crucial for developing therapeutic strategies.
- Zebrafish are valuable models for studying kidney injury and regeneration.
- Flow cytometry and TUNEL assays are used to assess cellular responses.
Purpose of Study
- To establish a zebrafish model of AKI using cisplatin.
- To evaluate inflammation and cell death in renal tissues.
- To explore potential therapeutic targets for renal protection.
Methods Used
- Anesthetizing and weighing zebrafish for cisplatin injection.
- Monitoring fish for recovery and mortality post-injection.
- Isolating renal cells for flow cytometry analysis.
- Performing TUNEL assays to detect apoptotic cells.
Main Results
- Cisplatin induces a dose-dependent mortality rate in zebrafish.
- Flow cytometry provides quantitative insights into inflammatory states.
- TUNEL assays reveal the presence of apoptotic cells in kidney tissue.
- The model can be utilized for further research on renal regeneration.
Conclusions
- The zebrafish model effectively mimics AKI for research purposes.
- Cisplatin serves as a useful tool for studying nephrotoxicity.
- Findings may contribute to the development of renal protective therapies.
Frequently Asked Questions
What is the role of cisplatin in this study?
Cisplatin is used as a nephrotoxic agent to induce Acute Kidney Injury in zebrafish.
How is kidney injury assessed in this model?
Kidney injury is assessed using flow cytometry and TUNEL assays to analyze inflammation and cell death.
What are the benefits of using zebrafish in kidney research?
Zebrafish provide a transparent model for observing kidney injury and regeneration processes in vivo.
What is the expected mortality rate after cisplatin injection?
Approximately 30% mortality is expected within the first 24 hours post-injection.
What techniques are used to analyze renal tissue?
Flow cytometry and TUNEL assays are employed to evaluate cellular responses in renal tissue.
Can this model be used for therapeutic testing?
Yes, this zebrafish model can be utilized to explore new therapeutic targets for renal protection.
Executive Industry Relevance
This protocol establishes a zebrafish model of cisplatin-induced acute kidney injury (AKI) to evaluate nephrotoxic mechanisms and inflammatory responses. It enables quantitative assessment of cell death and immune cell infiltration, supporting target validation and mechanistic de-risking in renal protection programs. The model provides a scalable, reproducible system for early discovery of compounds that mitigate cisplatin-induced kidney damage.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of cisplatin-induced tubular cell death and neutrophil infiltration as measurable endpoints for target validation.
- Operational Value: Provides a dose-dependent, quantifiable readout of nephrotoxicity via flow cytometry and TUNEL assay for hypothesis testing.
- Predictive Value: Supports mechanistic de-risking by linking cisplatin exposure to apoptosis and inflammation in a vertebrate kidney model.
Screening & Assay Development
- Scientific Value: Generates standardized renal tissue preparations suitable for flow cytometry and apoptosis screening in drug discovery campaigns.
- Operational Value: Enables high-content, quantitative analysis of immune cell populations and apoptotic cells using established zebrafish kidney dissociation protocols.
- Scalability: Supports reproducible isolation of kidney cells from adult zebrafish for multi-well plate-based screening workflows.
Translational & Preclinical Research
- Scientific Value: Models conserved mammalian AKI pathways, including tubular apoptosis and neutrophil-mediated inflammation, for translational biomarker alignment.
- Operational Value: Facilitates preclinical evaluation of renoprotective compounds by measuring reductions in cisplatin-induced cell death and immune infiltration.
- Predictive Confidence: Enables risk-adjusted advancement decisions based on dose-responsive histopathological and cytometric readouts.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target validation to lead identification, providing a disease-relevant system for assessing nephrotoxicity and renoprotection.
- Discovery Biology: Supports hypothesis testing of cisplatin-induced kidney injury through quantifiable apoptosis and neutrophil infiltration metrics.
- Screening: Enables assay-ready renal tissue preparation for flow cytometry-based immune profiling and TUNEL-based apoptosis detection.
- Analytics: Delivers quantitative readouts of cell death (TUNEL+) and inflammatory cell populations (MPO+ neutrophils) for comparative condition analysis.
- Translational Research: Connects zebrafish kidney injury mechanisms to mammalian AKI through conserved pathways of tubular apoptosis and inflammation.
- Enterprise Reuse: Establishes a reusable platform for nephrotoxicity screening and mechanistic studies across multiple therapeutic programs.
Operational & Enterprise Impact
- Scientific Value: Provides predictive confidence in target validation by modeling cisplatin-induced apoptosis and inflammation in a vertebrate kidney.
- Operational Value: Ensures reproducibility through standardized cisplatin dosing, kidney dissection, and cellular isolation protocols.
- Strategic Value: Improves go/no-go decisions by enabling early detection of nephrotoxic liability in lead compounds.
- Portfolio Impact: Supports risk-adjusted prioritization of renoprotective candidates based on quantifiable reductions in AKI biomarkers.
Implementation Considerations
- Requires expertise in zebrafish handling, anesthesia, and intraperitoneal injection techniques.
- Dependent on access to flow cytometers, fluorescence microscopes, and standard histology equipment for TUNEL processing.
- Necessitates standardization of cisplatin preparation, dosing calculations, and post-injection monitoring across operators.
- Involves adaptation considerations for kidney isolation in different zebrafish strains or sizes.
- Limited by the 24-hour post-injection window for peak apoptosis and neutrophil infiltration signals described in the protocol.
Biopharma FAQs
Why is neutrophil quantification important for target validation in AKI models?
Neutrophil infiltration, measured via MPO+ cell flow cytometry, serves as a quantitative biomarker of inflammation in cisplatin-induced kidney injury, enabling target validation of anti-inflammatory pathways.
How does isolating renal cells enable mechanistic de-risking in discovery pipelines?
Isolating kidney cells allows quantitative flow cytometry analysis of hematopoietic populations, enabling mechanistic de-risking by linking compound treatment to changes in immune cell profiles and apoptosis rates.
What quantitative measurements does the TUNEL assay enable for predictive confidence?
The TUNEL assay enables quantification of apoptotic cells in kidney tissue, providing a dose-dependent readout of cisplatin-induced nephrotoxicity that supports predictive confidence in renoprotective compound screening.
Why are replication requirements critical for cross-functional collaboration in AKI model adoption?
Replication ensures consistent cisplatin-induced mortality (~30% at 24 hpi) and biomarker responses across labs, enabling reliable data sharing between discovery, toxicology, and translational teams.
What statistical analysis capabilities are required before implementing this model in screening campaigns?
Implementation requires statistical power to detect significant changes in neutrophil infiltration and apoptotic cell counts, supporting go/no-go decisions based on reproducible, quantitative endpoints from flow cytometry and TUNEL assays.
